I-Mab

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

ROCKVILLE, MD, U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy of Cancer's (SITC) Annual Meeting, taking place November 1-5, 2023, in San Diego, California. The full text of the abstracts has been released on the SITC website, and the posters will be available on the Company's website following the conclusion of SITC 2023.

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

ROCKVILLE, Md. and SHANGHAI, China , Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that the updated clinical results from its Phase 1 study of givastomig (also known as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, on Monday, October 23 at 12:00 p.m.

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

-        Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached -        Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039 ROCKVILLE, Md. and SHANGHAI, Oct. 10, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced multiple recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio (Kosdaq: 298380).

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

AbbVie

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.

AbbVie terminates deal with I-Mab to develop cancer drug

Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has a late-stage pipeline with 20 assets and over $400 million in cash, but its market cap is only around $126 million. The company's advanced products, such as Felzartamab and Eftansomatropin Alfa, have limited trial data available, making it difficult for American investors to assess the company properly.

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

I-Mab Announces Upcoming Participation at September Conferences

I-Mab (NASDAQ:IMAB ) Q2 2023 Earnings Call Transcript August 17, 2023 8:00 AM ET Company Participants Tyler Ehler - Senior Director for IR Raj Kannan - CEO John Hayslip - CMO Richard Yeh - Interim CFO and COO Andrew Zhu - President and Head of R&D Conference Call Participants Kelly Shi - Jefferies Joe Catanzaro - Piper Sandler Louise Chen - Cantor Fitzgerald Gil Blum - Needham & Company Andres Maldonado - H.C. Wainwright Xiaoyi Qu - CICC Bing Zhao - China Renaissance Zhuxuan Jiang - CITIC Securities Tyler Ehler Good morning, everyone, and thank you for joining us this morning and for standing by.

I-Mab (IMAB) Q2 2023 Earnings Call Transcript

Significant progress made year-to-date on key clinical assets:‐         Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023‐         Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including patients with low levels of Claudin 18.2 tumor expression. Data to be presented at ESMO 2023 Eftansomatropin alfa (long-acting recombinant human growth hormone): Phase 3 pivotal study evaluating weekly injection of eftansomatropin alfa met the primary endpoint of annualized height velocity at week 52 and demonstrated non-inferiority to Norditropin®, administered by daily injection.

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

ROCKVILLE, Md. and SHANGHAI , Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023, before the market opens on Thursday, August 17, 2023, and host a conference call to discuss the results and provide corporate updates at 8:00 a.m.

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

GAITHERSBURG, Md. and SHANGHAI , July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering  immunotherapies, today announced the publication of a manuscript entitled "CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation" in the latest issue of T he Journal for Immuno-Therapy of Cancer (JITC).

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr.

I-Mab Announces the Appointment of Raj Kannan as CEO

-  Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells. -  In newly diagnosed patients who were not eligible for or declined chemotherapy treatment, 63% of the patients with CD73High  and PD-L1 TPS≥1% responded to the combination therapy while the response rate was 31% in all patients regardless of CD73 or PD-L1 expression.

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

GAITHERSBURG, Md. and SHANGHAI , May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission ("SEC") on May 1, 2023.

I-MAB Filed 2022 Annual Report on Form 20-F

GAITHERSBURG, Md. and SHANGHAI , April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of uliledlimab, the Company's proprietary and highly differentiated CD73 antibody, in combination with PD-1 therapy in non-small-cell lung cancer (NSCLC), will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6 in Chicago, Illinois.

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to Tracon Tribunal confirmed the termination of both agreements with Tracon I-Mab will accelerate the development and global partnership for uliledlimab and bi-specific antibody assets, which have the potential to create substantial value for the Company as soon as early 2024 GAITHERSBURG, Md. and SHANGHAI , April 25, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the positive outcome of its arbitration with TRACON Pharmaceuticals ("Tracon") relating to (1) the collaboration agreement to co-develop I-Mab's proprietary CD73 antibody, uliledlimab (TJD5) (the "TJD5 Agreement"), and (2) the collaboration agreement to potentially co-develop I-Mab's bi-specific antibodies (the "BsAb Agreement").

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

GAITHERSBURG, Md. and SHANGHAI , April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational trial (ClinicalTrials.gov Identifier: NCT05709093) in China for patients with higher-risk myelodysplastic syndrome (MDS) has been treated with lemzoparlimab, a novel CD47 antibody, in combination with azacitidine (AZA).

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

I-Mab (NASDAQ:IMAB ) Q4 2022 Earnings Conference Call March 31, 2023 8:15 AM ET Company Participants Tyler Ehler - Senior Director of Investor Relations Andrew Zhu - Acting Chief Executive Officer Richard Yeh - Interim Chief Financial Officer and Chief Operating Officer Jingwu Zang - Founder and Chairman Conference Call Participants Kelly Shi - Jefferies Joseph Catanzaro - Piper Sandler Louise Chen - Cantor Fitzgerald Andres Maldonado - H.C. Wainwright Tyler Ehler Good morning to everyone and thank you for joining us this morning.

I-Mab (IMAB) Q4 2022 Earnings Call Transcript

Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus Thirteen key clinical milestones achieved in 2022, including positive data readout for lemzoparlimab, uliledlimab, and givastomig and significant progress on eftansomatropin alfa and felzartamab. Phase 3 data readout of eftansomatropin alfa and potential biologics license applications ("BLA") submission expected by the end of 2023 or early 2024 I-Mab and AbbVie continue to collaborate on the global development of anti-CD47 antibody therapy under an amendment to the original agreement A strong cash position of RMB3.5 billion (US$514.2 million) by the end of 2022, sufficient to fund key business operations for the next three years I-Mab will host conference calls and webcasts on March 31, 2023.

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

GAITHERSBURG, Md. and SHANGHAI, China , March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m.

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

GAITHERSBURG, MD. and SHANGHAI , March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan Stanley Capital International) ESG, following MSCIESG's most recent annual review, and such rating outperforms 66% peers among global biotech companies.

MSCI ESG Updated I-Mab to "A" Rating

GAITHERSBURG, MD. and SHANGHAI , Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and translational research data of lemzoparlimab, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022, in New Orleans, Louisiana.

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

Los Angeles, California--(Newsfile Corp. - October 10, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab ("I-Mab" or "the Company") (NASDAQ: IMAB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm

IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks

GAITHERSBURG, MD. and SHANGHAI, China , Oct. 5, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022.

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

Clearance from China was received to initiate a phase 3 registrational study using Lemzoparlimab for high-risk MDS patients; trial initiation is expected in Q4 of 2022. Results from phase 2 studies using uliledlimab for the treatment of patients with non-small cell lung cancer are expected in Q4 of 2022.

News for I-Mab Stock (IMAB)